Importantly, only when LTβR agonist treatment was combined with dual ICB were there significant increases in CD8+ tumour infiltrating lymphocytes (TILs) which were accompanied by improved responses to therapy and tumour regression [12]. Here, CD8A is linked to neoplasm.